If you are attending #BIO2024 we invite you to attend a panel featuring Steven Spector, Longboard’s EVP, Head of Business Development and General Counsel, and other esteemed speakers, for a discussion regarding the biotech IPO landscape. https://bit.ly/4aDagW7
Longboard Pharmaceuticals’ Post
More Relevant Posts
-
Expect more reverse mergers in biotech before year's end. This week's showings — Graphite Bio Lenz Therapeutics and Homology Medicines Q32 Bio — are likely just the beginning as the IPO path remains icy. “We really saw companies lining up for the fourth quarter and going out and also accelerating timelines, and that all really slowed down after the outbreak of the war because people were unsure what was going to happen,” Jordan Saxe, head of healthcare listings at Nasdaq, told Endpoints News. “That pause was just enough to slow down the market at the end of the year where we had just started to get some momentum.” Saxe foresees about five to eight listings in the first quarter of 2024, with next year looking "very similar to this year, but maybe a slight uptick" in IPOs for the industry. Drug developers looking to go public are facing stiff walls on Wall Street as the go-go period of 2020 and 2021 is far in the rearview. #biotech #ipo #initialpublicoffering #nasdaq #lifesciences #drugdevelopment #startup #venturecapital #biopharma #wallstreet #reversemerger #mergers
To view or add a comment, sign in
-
Listings of biotech companies on the Hong Kong Stock Exchange in 2023 were muted but remain steady in comparison to 2022. Our team in Hong Kong analyzed the key features of these companies and their listings, including status and maturity of a company at IPO, IPO size, corporate governance aspects and post-IPO performance. https://lnkd.in/e_vSiAcr Paloma Wang | Kai Sun | Anthony Pang | Martina To | Lillian Lian #capitalmarkets #regulatory #biotech #asiapacific
To view or add a comment, sign in
-
-
Concord Biotech LTD IPO is now open! #SBISecurities #IPO #StockMarket #ConcordBiotech #ConcardIPO #Biotech #ShareMarket #Finance #Investment #Invest #HappyInvesting #Stocks #StockUpdates #Investmentopportunities #WealthCreation #StockMarketUpdate #StayInvested #FinancialGrowth #Biopharma #InvestinIPO
To view or add a comment, sign in
-
-
Sharing our latest IPO tracker update: 📈 3Q 2023 has been a robust quarter for IPOs! Biotech companies made their public debut via an IPO in Q3 raising ~$1 billion. RayzeBio and Apogee Therapeutics are trading above their debut share price. A total of 36 operating companies went public via traditional IPOs, while 30 took the SPAC route. Exciting times ahead! #IPO #MarketTrends #3Q2023"
To view or add a comment, sign in
-
-
“Venturing Forward, Innovating for Impact” | Managing Partner | Venture Capital, Strategic M&A Advisory, Investment Banking | Board of Directors | Healthcare, Life Sciences, and Frontier
In the dynamic world of biotechnology, reverse mergers are becoming an increasingly popular strategy to access the public capital markets relative to a traditional S-1. While they offer a quicker route to public markets compared to traditional IPOs, it's crucial to understand both the opportunities and challenges they present. As with any strategic decision, careful consideration must be key. Biotech leaders must weigh these factors to ensure a reverse merger aligns with their long-term goals and stakeholder interests. They are not a viable alternative for many. Given the existence of about 220 negative enterprise value biotech companies currently on the market, expect more supply and demand interest in these "strategic alternative plays". Oh ya, don't forget that many of these microcap publics don't have enough cash post transaction to support working capital requirements for MergeCo so a PIPE will need to be considered in parallel. #Biotech #ReverseMerger #IPO #Biotechnology #BusinessStrategy
Biotech’s IPO outlook for the rest of the year sours in wake of war, broader industry struggles
https://endpts.com
To view or add a comment, sign in
-
𝐀𝐫𝐞 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐈𝐏𝐎𝐬 𝐬𝐞𝐭 𝐟𝐨𝐫 𝐚 𝐫𝐞𝐬𝐮𝐫𝐠𝐞𝐧𝐜𝐞 𝐢𝐧 𝟮𝟬𝟮𝟰? Over the last two years, the biotech IPO scene has been relatively quite. Yet, a recent market upswing in the last quarter of 2023 hints at a potential revival of IPOs this year. The strong performance of biotech stocks last quarter, driven by the US Fed's stance on rates and notable mergers, suggests that unless a significant economic shock occurs, biotech stands to benefit from investors' increased risk appetite this year. It’s not likely that 2024 will mirror 2020 or 2021, the history of swift shifts in risk tolerance suggests the possibility of a substantial uptick in IPO activity. A great and insightful read from Richard Murphey and Bay Bridge Bio, check it out!
Is the biotech IPO boom fading?
baybridgebio.com
To view or add a comment, sign in
-
Are you a U.K. biotech stakeholder interested in harnessing the low volatility and large investor pool of the U.S. IPO market? There are a few hurdles to clear before you can close your transaction, and our eBook lays out the best approach to overcoming them. Read it now: https://bit.ly/450kZHp #CFGI #UK #Biotech #GoingPublic #IPO
A Guide to Bringing a UK Biotech Company to US Public Markets - CFGI
https://www.cfgi.com
To view or add a comment, sign in
-
Download our FREE case study eBook and talk to a CFGI partner today! 🙌🏻
Are you a U.K. biotech stakeholder interested in harnessing the low volatility and large investor pool of the U.S. IPO market? There are a few hurdles to clear before you can close your transaction, and our eBook lays out the best approach to overcoming them. Read it now: https://bit.ly/450kZHp #CFGI #UK #Biotech #GoingPublic #IPO
A Guide to Bringing a UK Biotech Company to US Public Markets - CFGI
https://www.cfgi.com
To view or add a comment, sign in
-
Chinese biotech Adlai Nortye has delayed its Nasdaq IPO after the US market regulator refused to clear the deal because of the language used for risk disclosure, according to people familiar with the situation. Subscribe to read the full story at www.ifre.com
To view or add a comment, sign in
-
-
Initial public offerings (IPOs) are a critical step in the capital formation path for the #biotech industry, providing companies with the public capital they need to advance to their next phase of growth. Considering a 2024 #IPO? One of the crucial elements of IPO preparedness is developing your SEC Form S-1. Delivering a document that effectively tells your corporate story is key to a successful outcome for your IPO process. Learn how MacDougall can support your S-1 Form writing: bit.ly/3ravYQV Questions? Reach out to our team: [email protected] #scicomms #lifesciences
To view or add a comment, sign in
-
Head of Investor Relations at Longboard Pharmaceuticals
1moGoing to be a great panel!